FDA Clearance Tracker · P870077
CARPENTIER-EDWARDS DURAFLEX LOW PRESSURE MITRAL BIOPROSTHESIS
Last checked: Nov 20, 2026Latest source record: Sep 25, 1991 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 1991
Approval withdrawn
Time to decision
1,388 days
Received Dec 7, 1987. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P870077
- Device name
- CARPENTIER-EDWARDS DURAFLEX LOW PRESSURE MITRAL BIOPROSTHESIS
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Dec 7, 1987
- Decided
- Sep 25, 1991
- Decision
- Approval withdrawn
- Supplements
- 56 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- replacement Heart-valve (DYE)
- Device class
- Class III
- Regulation
- 21 CFR 870.3925
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the Carpentier-Edwards® Duraflex Bioprosthesis, Models 6625 LP and 6625-ESR-LP. These devices are intended for use in patients whose mitral valvular disease is sufficiently advanced to warrant replacement of their natural valve with a prosthetic one. It is also intended for use in patients with a previously implanted mitral valve prosthesis which is no longer functioning adequately and requires replacement.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code DYE. The earliest in FDA's data is P870078, decided Sep 28, 1989.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.